• KOL
    • Heart Failure
    • John J J V Mcmurray
    • John J J V McMurray: Influence Statistics

      John J J V McMurray

      John J J V McMurray

      Show email address

      British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom (P.D., K.F.D., P.S.J., J.J.V.M.). | British Heart Foundation ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      John J J V McMurray:Expert Impact

      Concepts for whichJohn J J V McMurrayhas direct influence:Heart failure,Patients heart failure,Myocardial infarction,Chronic heart failure,Atrial fibrillation,Reduced ejection fraction,Preserved ejection fraction,Ejection fraction.

      John J J V McMurray:KOL impact

      Concepts related to the work of other authors for whichfor which John J J V McMurray has influence:Heart failure,Atrial fibrillation,Myocardial infarction,Cardiovascular disease,Type 2 diabetes,Preserved ejection fraction,Blood pressure.

      KOL Resume for John J J V McMurray

      Year
      2022

      British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom (P.D., K.F.D., P.S.J., J.J.V.M.).

      BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, United Kingdom

      Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

      University of Glasgow, UK.

      Cardiology Division, Cardiovascular Department, Azienda Ospedaliera Papa Giovanni XXIII Hospital, Bergamo, Italy

      2021

      Glasgow University, Institute of Cardiovascular and Medical Sciences, Glasgow, United Kingdom

      Sign-in to see all concepts, it's free!
      Sample of concepts for which John J J V McMurray is among the top experts in the world.
      Concept World rank
      heart failure assessment #1
      dapagliflozin diuretic patients #1
      paragon hf #1
      trial cardiovascular events #1
      irbesartan heart #1
      hf atrasentan #1
      patients paradigmhf #1
      nolomirole #1
      placebo primary #1
      congenital pah #1
      neprilysin stroke #1
      cardiovascular rosuvastatin #1
      clinical summary score #1
      eligibility dapagliflozin #1
      patients mra #1
      estimated 5 #1
      weekly “one #1
      versus irbesartan #1
      nondominant brachial artery #1
      atrasentan sonar trial #1
      np copd #1
      p0001 allcause mortality #1
      gain eventfree time #1
      mlhfq scores irbesartan #1
      hf worsening #1
      increased uacr patients #1
      hfref wrf #1
      redhf trial #1
      hfpef raas inhibitors #1
      valiant trial #1
      hfmef hfref #1
      outcomes adjusted #1
      apixaban imputed placebo #1
      16224 #1
      hf cachexia #1
      clinical benefit dapagliflozin #1
      ascend‐hf biomarker substudy #1
      nct00097786 #1
      altitude trial #1
      oral azd9977 #1
      33121 #1
      mra paragonhf #1
      spvu #1
      empareg outcomes #1
      ipreserve trial #1
      versus enalapril #1
      n3241 #1
      substance peak #1
      failure death sacubitrilvalsartan #1
      patients sacubitril #1
      Sign-in to see all concepts, it's free!

      Prominent publications by John J J V McMurray

      KOL-Index: 22875

      BACKGROUND: Patients with stable coronary artery disease and diabetes with previous percutaneous coronary intervention (PCI), particularly those with previous stenting, are at high risk of ischaemic events. These patients are generally treated with aspirin. In this trial, we aimed to investigate if these patients would benefit from treatment with aspirin plus ticagrelor.

      METHODS: The Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) was a ...

      Known for Coronary Artery | Ticagrelor Patients | Previous Pci | Cardiovascular Death | Myocardial Infarction
      KOL-Index: 21327

      BACKGROUND: Goals of management in patients with heart failure and reduced ejection fraction include reducing death and hospitalizations, and improving health status (symptoms, physical function, and quality of life). In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure), sodium-glucose cotransporter-2 inhibitor, dapagliflozin, reduced death and hospitalizations, and improved symptoms in patients with heart failure and reduced ejection fraction. In this ...

      Known for Heart Failure | Reduced Ejection Fraction | Patients Dapagliflozin | Quality Life | Summary Score
      KOL-Index: 20061

      BACKGROUND: Dapagliflozin reduces the risk of kidney failure and heart failure in patients with chronic kidney disease. We aimed to investigate the effects of dapagliflozin on kidney, cardiovascular, and mortality outcomes according to presence or absence of type 2 diabetes and according to underlying cause of chronic kidney disease, reported as diabetic nephropathy, chronic glomerulonephritides, ischaemic or hypertensive chronic kidney disease, or chronic kidney disease of other or ...

      Known for Chronic Kidney | Cardiovascular Events | Heart Failure | Diabetic Nephropathy | Participants Dapagliflozin
      KOL-Index: 19833

      OBJECTIVES: This study sought to understand prognostic implications of increased baseline left ventricular (LV) mass and geometric patterns in a high risk acute myocardial infarction.

      BACKGROUND: The LV hypertrophy and alterations in LV geometry are associated with an increased risk of adverse cardiovascular events.

      METHODS: Quantitative echocardiographic analyses were performed at baseline in 603 patients from the VALIANT (VALsartan In Acute myocardial iNfarcTion) echocardiographic ...

      Known for Ventricular Mass | Prognostic Implications | Lvmi Rwt | Myocardial Infarction | Lv Geometry
      KOL-Index: 18973

      BACKGROUND: Patients with symptomatic chronic heart failure (CHF) and reduced left ventricular ejection fraction (LVEF) have a high risk of death and hospitalization for CHF deterioration despite therapies with angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, and even an aldosterone antagonist. To determine whether the angiotensin-receptor blocker (ARB) candesartan decreases cardiovascular mortality, morbidity, and all-cause mortality in patients with CHF and depressed ...

      Known for Patients Candesartan | Ace Inhibitors | Cardiovascular Death | Allcause Mortality | Ventricular Systolic Dysfunction
      KOL-Index: 18485

      Importance: Additional treatments are needed for heart failure with reduced ejection fraction (HFrEF). Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be an effective treatment for patients with HFrEF, even those without diabetes.

      Objective: To evaluate the effects of dapagliflozin in patients with HFrEF with and without diabetes.

      Design, Setting, and Participants: Exploratory analysis of a phase 3 randomized trial conducted at 410 sites in 20 countries. Patients with New York ...

      Known for Dapagliflozin Patients | Cardiovascular Death | Heart Failure | Hazard Ratio | Exploratory Analysis
      KOL-Index: 18453

      BACKGROUND: We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, enalapril improved survival in such patients.

      METHODS: In this double-blind trial, we randomly assigned 8442 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either LCZ696 (at a dose of 200 mg twice daily) or enalapril (at a dose of 10 mg twice daily), in ...

      Known for Heart Failure | Lcz696 Enalapril | Death Hospitalization | Hazard Ratio | P0001 Patients
      KOL-Index: 18409

      BACKGROUND: Vitamin K antagonists are highly effective in preventing stroke in patients with atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa inhibitor that has been shown to reduce the risk of stroke in a similar population in comparison with aspirin.

      METHODS: In this randomized, double-blind trial, we compared apixaban (at a dose of 5 mg twice daily) with warfarin (target international normalized ratio, 2.0 to 3.0) in 18,201 patients with ...

      Known for Atrial Fibrillation | Year Apixaban | Warfarin Hazard Ratio | Rates Death | Stroke Patients
      KOL-Index: 18405

      OBJECTIVES: The study sought to investigate the safety and efficacy of eplerenone in patients at high risk for hyperkalemia or worsening renal function (WRF) in EMPHASIS-HF, a trial that enrolled patients at least 55 years old with heart failure and reduced ejection fraction (HF-REF), in New York Heart Association (NYHA) functional class II and with an estimated glomerular filtration rate (eGFR) >30 ml/min/1.73 m(2) and serum potassium <5.0 mmol/l. Patients were receiving optimal therapy ...

      Known for Eplerenone Patients | Renal Function | Risk Hyperkalemia | Survival Study | Heart Failure
      KOL-Index: 18211

      BACKGROUND: The Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial showed that apixaban is better than warfarin at prevention of stroke or systemic embolism, causes less bleeding, and results in lower mortality. We assessed in this trial's participants how results differed according to patients' CHADS(2), CHA(2)DS(2)VASc, and HAS-BLED scores, used to predict the risk of stroke and bleeding.

      METHODS: ARISTOTLE was a double-blind, ...

      Known for Atrial Fibrillation | Apixaban Warfarin | Risk Stroke | Secondary Analysis | Systemic Embolism
      KOL-Index: 17999

      BACKGROUND: The effect of the α-glucosidase inhibitor acarbose on cardiovascular outcomes in patients with coronary heart disease and impaired glucose tolerance is unknown. We aimed to assess whether acarbose could reduce the frequency of cardiovascular events in Chinese patients with established coronary heart disease and impaired glucose tolerance, and whether the incidence of type 2 diabetes could be reduced.

      METHODS: The Acarbose Cardiovascular Evaluation (ACE) trial was a ...

      Known for Impaired Glucose Tolerance | Coronary Heart Disease | Cardiovascular Death | Chinese Patients | Diabetes Outcomes
      KOL-Index: 17984

      BACKGROUND: Although most patients in the PARADIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial had mild symptoms, there is a poor correlation between reported functional limitation and prognosis in heart failure.

      OBJECTIVES: The aim of this study was to examine the spectrum of risk in PARADIGM-HF and the effect of LCZ696 across that spectrum.

      METHODS: This study analyzed rates of the primary composite outcome ...

      Known for Baseline Risk | Lcz696 Enalapril | Heart Failure | Global Mortality | Cardiovascular Death
      KOL-Index: 17951

      BACKGROUND: The importance of endothelin-1 in chronic heart failure (CHF) is unclear. We therefore investigated the effects of endothelin-converting enzyme (ECE) inhibition and endothelin ETA receptor blockade in CHF patients treated with ACE inhibitors. We also compared the function of ETA and ETB receptors in healthy subjects and patients with CHF.

      METHODS AND RESULTS: Locally active doses of study drugs were infused into the nondominant brachial artery while forearm blood flow (FBF ...

      Known for Eta Receptor | Chf Patients | Chronic Heart | Converting Enzyme | Ace Inhibitors
      KOL-Index: 17837

      BACKGROUND: Anemia is associated with an increased risk of cardiovascular and renal events among patients with type 2 diabetes and chronic kidney disease. Although darbepoetin alfa can effectively increase hemoglobin levels, its effect on clinical outcomes in these patients has not been adequately tested.

      METHODS: In this study involving 4038 patients with diabetes, chronic kidney disease, and anemia, we randomly assigned 2012 patients to darbepoetin alfa to achieve a hemoglobin level of ...

      Known for Darbepoetin Alfa | Chronic Kidney Disease | Type 2 Diabetes | Hazard Ratio | Cardiovascular Event
      KOL-Index: 17728

      BACKGROUND: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke.

      METHODS: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned ...

      Known for Type 2 Diabetes | Cardiovascular Disease | Patients Placebo | Harmony Outcomes | Myocardial Infarction

      Key People For Heart Failure

      Top KOLs in the world
      #1
      John J J V McMurray
      heart failure myocardial infarction atrial fibrillation
      #2
      John George Franklin Cleland
      heart failure patients hf atrial fibrillation
      #3
      Stephan D Anker
      heart failure iron deficiency cardiac cachexia
      #4
      Greegg C Fonarow
      heart failure atrial fibrillation united states
      #5
      Karl B Swedberg
      heart failure reduced ejection fraction myocardial infarction
      #6
      Piotr P Ponikowski
      heart failure iron deficiency reduced ejection fraction

      British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom (P.D., K.F.D., P.S.J., J.J.V.M.). | British Heart Foundation Cardiovascular Research Centre, University of Glasgow, UK (J.J.V.M.). | British Heart

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.